Grid performance test to measure behavioral impairment in the MPTP-treated-mouse model of parkinsonism - PubMed (original) (raw)

Comparative Study

. 2003 Mar 15;123(2):189-200.

doi: 10.1016/s0165-0270(02)00360-6.

Affiliations

• PMID: 12606067
• DOI: 10.1016/s0165-0270(02)00360-6

Comparative Study

Grid performance test to measure behavioral impairment in the MPTP-treated-mouse model of parkinsonism

Jennifer L Tillerson et al. J Neurosci Methods. 2003.

Abstract

Behavioral impairments in mice following administration of the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) require large depletions in striatal dopamine content and are often transient. In this paper, we describe a simple and inexpensive test that measures long-term behavioral deficits in mice treated with moderate doses of MPTP. These measures are significantly correlated with the loss of striatal dopamine and immunoreactivity of the dopamine transporter, vesicular monoamine transporter and tyrosine hydroxylase. In addition, behavioral impairments on the measures were reversed following L-DOPA administration. Employment of this test will allow for more efficacious use of mice in PD research, as well as provide more sensitive measures of behavioral improvement following potential therapeutic or neuroprotective interventions.

PubMed Disclaimer

Similar articles

• Detection of behavioral impairments correlated to neurochemical deficits in mice treated with moderate doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
  Tillerson JL, Caudle WM, Reverón ME, Miller GW. Tillerson JL, et al. Exp Neurol. 2002 Nov;178(1):80-90. doi: 10.1006/exnr.2002.8021. Exp Neurol. 2002. PMID: 12460610
• Aging of the dopaminergic system and motor behavior in mice intoxicated with the parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
  Schumm S, Sebban C, Cohen-Salmon C, Callebert J, Launay JM, Golmard JL, Boussicault L, Petropoulos I, Hild A, Rousselet E, Prigent A, Friguet B, Mariani J, Hirsch EC. Schumm S, et al. J Neurochem. 2012 Sep;122(5):1032-46. doi: 10.1111/j.1471-4159.2012.07837.x. Epub 2012 Jul 11. J Neurochem. 2012. PMID: 22708926
• The intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a new rodent model to test palliative and neuroprotective agents for Parkinson's disease.
  Prediger RD, Aguiar AS Jr, Moreira EL, Matheus FC, Castro AA, Walz R, De Bem AF, Latini A, Tasca CI, Farina M, Raisman-Vozari R. Prediger RD, et al. Curr Pharm Des. 2011;17(5):489-507. doi: 10.2174/138161211795164095. Curr Pharm Des. 2011. PMID: 21375482 Review.
• Obligatory role for complex I inhibition in the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
  Richardson JR, Caudle WM, Guillot TS, Watson JL, Nakamaru-Ogiso E, Seo BB, Sherer TB, Greenamyre JT, Yagi T, Matsuno-Yagi A, Miller GW. Richardson JR, et al. Toxicol Sci. 2007 Jan;95(1):196-204. doi: 10.1093/toxsci/kfl133. Epub 2006 Oct 12. Toxicol Sci. 2007. PMID: 17038483
• [A mouse model of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induced parkinsonism: effect of norepinephrine terminal destruction].
  Nishi K, Kondo T, Narabayashi H. Nishi K, et al. No To Shinkei. 1987 Jul;39(7):663-72. No To Shinkei. 1987. PMID: 3314916 Review. Japanese.

Cited by

• Idebenone and resveratrol extend lifespan and improve motor function of HtrA2 knockout mice.
  Gerhardt E, Gräber S, Szego EM, Moisoi N, Martins LM, Outeiro TF, Kermer P. Gerhardt E, et al. PLoS One. 2011;6(12):e28855. doi: 10.1371/journal.pone.0028855. Epub 2011 Dec 19. PLoS One. 2011. PMID: 22205977 Free PMC article.
• Role of microtubule-associated protein 6 glycosylated with Gal-(β-1,3)-GalNAc in Parkinson's disease.
  Ma L, Song J, Sun X, Ding W, Fan K, Qi M, Xu Y, Zhang W. Ma L, et al. Aging (Albany NY). 2019 Jul 9;11(13):4597-4610. doi: 10.18632/aging.102072. Aging (Albany NY). 2019. PMID: 31289257 Free PMC article.
• Murine motor and behavior functional evaluations for acute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) intoxication.
  Hutter-Saunders JA, Gendelman HE, Mosley RL. Hutter-Saunders JA, et al. J Neuroimmune Pharmacol. 2012 Mar;7(1):279-88. doi: 10.1007/s11481-011-9269-4. Epub 2011 Mar 24. J Neuroimmune Pharmacol. 2012. PMID: 21431472 Free PMC article.
• Neural precursors cells expanded in a 3D micro-engineered niche present enhanced therapeutic efficacy in vivo.
  Carelli S, Giallongo T, Rey F, Barzaghini B, Zandrini T, Pulcinelli A, Nardomarino R, Cerullo G, Osellame R, Cereda C, Zuccotti GV, Raimondi MT. Carelli S, et al. Nanotheranostics. 2021 Jan 1;5(1):8-26. doi: 10.7150/ntno.50633. eCollection 2021. Nanotheranostics. 2021. PMID: 33391972 Free PMC article.
• Absence of Glia Maturation Factor Protects from Axonal Injury and Motor Behavioral Impairments after Traumatic Brain Injury.
  Selvakumar GP, Ahmed ME, Iyer SS, Thangavel R, Kempuraj D, Raikwar SP, Bazley K, Wu K, Khan A, Kukulka K, Bussinger B, Zaheer S, Burton C, James D, Zaheer A. Selvakumar GP, et al. Exp Neurobiol. 2020 Jun 30;29(3):230-248. doi: 10.5607/en20017. Exp Neurobiol. 2020. PMID: 32565489 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science

• Other Literature Sources

  • The Lens - Patent Citations Database